Cargando…
Glycosylated Nanoparticles for Cancer-Targeted Drug Delivery
Nanoparticles (NPs) are novel platforms that can carry both cancer-targeting molecules and drugs to avoid severe side effects due to nonspecific drug delivery in standard chemotherapy treatments. Cancer cells are characterized by abnormal membranes, metabolic changes, the presence of lectin receptor...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7735155/ https://www.ncbi.nlm.nih.gov/pubmed/33330106 http://dx.doi.org/10.3389/fonc.2020.605037 |
_version_ | 1783622602689871872 |
---|---|
author | Torres-Pérez, Sergio Andrés Torres-Pérez, Cindy Estefani Pedraza-Escalona, Martha Pérez-Tapia, Sonia Mayra Ramón-Gallegos, Eva |
author_facet | Torres-Pérez, Sergio Andrés Torres-Pérez, Cindy Estefani Pedraza-Escalona, Martha Pérez-Tapia, Sonia Mayra Ramón-Gallegos, Eva |
author_sort | Torres-Pérez, Sergio Andrés |
collection | PubMed |
description | Nanoparticles (NPs) are novel platforms that can carry both cancer-targeting molecules and drugs to avoid severe side effects due to nonspecific drug delivery in standard chemotherapy treatments. Cancer cells are characterized by abnormal membranes, metabolic changes, the presence of lectin receptors, glucose transporters (GLUT) overexpression, and glycosylation of immune receptors of programmed death on cell surfaces. These characteristics have led to the development of several strategies for cancer therapy, including a large number of carbohydrate-modified NPs, which have become desirable for use in cell-selective drug delivery systems because they increase nanoparticle-cell interactions and uptake of carried drugs. Currently, the potential of NP glycosylation to enhance the safety and efficacy of carried therapeutic antitumor agents has been widely acknowledged, and much information is accumulating in this field. This review seeks to highlight recent advances in NP stabilization, toxicity reduction, and pharmacokinetic improvement and the promising potential of NP glycosylation from the perspective of molecular mechanisms described for drug delivery systems for cancer therapy. From preclinical proof-of-concept to demonstration of therapeutic value in the clinic, the challenges and opportunities presented by glycosylated NPs, with a focus on their applicability in the development of nanodrugs, are discussed in this review. |
format | Online Article Text |
id | pubmed-7735155 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-77351552020-12-15 Glycosylated Nanoparticles for Cancer-Targeted Drug Delivery Torres-Pérez, Sergio Andrés Torres-Pérez, Cindy Estefani Pedraza-Escalona, Martha Pérez-Tapia, Sonia Mayra Ramón-Gallegos, Eva Front Oncol Oncology Nanoparticles (NPs) are novel platforms that can carry both cancer-targeting molecules and drugs to avoid severe side effects due to nonspecific drug delivery in standard chemotherapy treatments. Cancer cells are characterized by abnormal membranes, metabolic changes, the presence of lectin receptors, glucose transporters (GLUT) overexpression, and glycosylation of immune receptors of programmed death on cell surfaces. These characteristics have led to the development of several strategies for cancer therapy, including a large number of carbohydrate-modified NPs, which have become desirable for use in cell-selective drug delivery systems because they increase nanoparticle-cell interactions and uptake of carried drugs. Currently, the potential of NP glycosylation to enhance the safety and efficacy of carried therapeutic antitumor agents has been widely acknowledged, and much information is accumulating in this field. This review seeks to highlight recent advances in NP stabilization, toxicity reduction, and pharmacokinetic improvement and the promising potential of NP glycosylation from the perspective of molecular mechanisms described for drug delivery systems for cancer therapy. From preclinical proof-of-concept to demonstration of therapeutic value in the clinic, the challenges and opportunities presented by glycosylated NPs, with a focus on their applicability in the development of nanodrugs, are discussed in this review. Frontiers Media S.A. 2020-11-30 /pmc/articles/PMC7735155/ /pubmed/33330106 http://dx.doi.org/10.3389/fonc.2020.605037 Text en Copyright © 2020 Torres-Pérez, Torres-Pérez, Pedraza-Escalona, Pérez-Tapia and Ramón-Gallegos http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Torres-Pérez, Sergio Andrés Torres-Pérez, Cindy Estefani Pedraza-Escalona, Martha Pérez-Tapia, Sonia Mayra Ramón-Gallegos, Eva Glycosylated Nanoparticles for Cancer-Targeted Drug Delivery |
title | Glycosylated Nanoparticles for Cancer-Targeted Drug Delivery |
title_full | Glycosylated Nanoparticles for Cancer-Targeted Drug Delivery |
title_fullStr | Glycosylated Nanoparticles for Cancer-Targeted Drug Delivery |
title_full_unstemmed | Glycosylated Nanoparticles for Cancer-Targeted Drug Delivery |
title_short | Glycosylated Nanoparticles for Cancer-Targeted Drug Delivery |
title_sort | glycosylated nanoparticles for cancer-targeted drug delivery |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7735155/ https://www.ncbi.nlm.nih.gov/pubmed/33330106 http://dx.doi.org/10.3389/fonc.2020.605037 |
work_keys_str_mv | AT torresperezsergioandres glycosylatednanoparticlesforcancertargeteddrugdelivery AT torresperezcindyestefani glycosylatednanoparticlesforcancertargeteddrugdelivery AT pedrazaescalonamartha glycosylatednanoparticlesforcancertargeteddrugdelivery AT pereztapiasoniamayra glycosylatednanoparticlesforcancertargeteddrugdelivery AT ramongallegoseva glycosylatednanoparticlesforcancertargeteddrugdelivery |